MEDPACE HOLDINGS INC (MEDP) Stock Fundamental Analysis
NASDAQ:MEDP - US58506Q1094 - Common Stock
463.64 USD
+10.3 (+2.27%)
463.64 USD
0 (0%)
We assign a fundamental rating of 7 out of 10 to MEDP. MEDP was compared to 54 industry peers in the Life Sciences Tools & Services industry. MEDP has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. MEDP is not priced too expensively while it is growing strongly. Keep and eye on this one! With these ratings, MEDP could be worth investigating further for growth and quality investing!.
1. Profitability
1.1 Basic Checks
MEDP had positive earnings in the past year.
In the past year MEDP had a positive cash flow from operations.
Each year in the past 5 years MEDP has been profitable.
Each year in the past 5 years MEDP had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 26.61%, MEDP belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
With an excellent Return On Equity value of 242.70%, MEDP belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
With an excellent Return On Invested Capital value of 115.03%, MEDP belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for MEDP is significantly above the industry average of 16.00%.
The last Return On Invested Capital (115.03%) for MEDP is above the 3 year average (38.75%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 26.61% | ||
| ROE | 242.7% | ||
| ROIC | 115.03% |
ROA(3y)18.14%
ROA(5y)15.16%
ROE(3y)54.33%
ROE(5y)40%
ROIC(3y)38.75%
ROIC(5y)29.27%
1.3 Margins
The Profit Margin of MEDP (18.74%) is better than 92.59% of its industry peers.
MEDP's Profit Margin has improved in the last couple of years.
Looking at the Operating Margin, with a value of 21.40%, MEDP belongs to the top of the industry, outperforming 90.74% of the companies in the same industry.
MEDP's Operating Margin has improved in the last couple of years.
The Gross Margin of MEDP (31.62%) is worse than 68.52% of its industry peers.
MEDP's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.4% | ||
| PM (TTM) | 18.74% | ||
| GM | 31.62% |
OM growth 3Y6.82%
OM growth 5Y7.46%
PM growth 3Y6.48%
PM growth 5Y10.5%
GM growth 3Y2.7%
GM growth 5Y1.75%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), MEDP is creating value.
MEDP has less shares outstanding than it did 1 year ago.
MEDP has less shares outstanding than it did 5 years ago.
MEDP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
MEDP has an Altman-Z score of 6.85. This indicates that MEDP is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 6.85, MEDP belongs to the top of the industry, outperforming 88.89% of the companies in the same industry.
MEDP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 6.85 |
ROIC/WACC10.88
WACC10.57%
2.3 Liquidity
MEDP has a Current Ratio of 0.43. This is a bad value and indicates that MEDP is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.43, MEDP is not doing good in the industry: 98.15% of the companies in the same industry are doing better.
MEDP has a Quick Ratio of 0.43. This is a bad value and indicates that MEDP is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.43, MEDP is not doing good in the industry: 96.30% of the companies in the same industry are doing better.
The current and quick ratio evaluation for MEDP is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.43 | ||
| Quick Ratio | 0.43 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 26.53% over the past year.
Measured over the past years, MEDP shows a very strong growth in Earnings Per Share. The EPS has been growing by 33.22% on average per year.
The Revenue has grown by 9.94% in the past year. This is quite good.
The Revenue has been growing by 19.62% on average over the past years. This is quite good.
EPS 1Y (TTM)26.53%
EPS 3Y37.96%
EPS 5Y33.22%
EPS Q2Q%12.73%
Revenue 1Y (TTM)9.94%
Revenue growth 3Y22.68%
Revenue growth 5Y19.62%
Sales Q2Q%14.24%
3.2 Future
Based on estimates for the next years, MEDP will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.11% on average per year.
The Revenue is expected to grow by 11.19% on average over the next years. This is quite good.
EPS Next Y13.45%
EPS Next 2Y11.66%
EPS Next 3Y11.54%
EPS Next 5Y10.11%
Revenue Next Year16.8%
Revenue Next 2Y12.77%
Revenue Next 3Y11.6%
Revenue Next 5Y11.19%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 34.47, the valuation of MEDP can be described as expensive.
Based on the Price/Earnings ratio, MEDP is valued a bit cheaper than the industry average as 62.96% of the companies are valued more expensively.
MEDP is valuated rather expensively when we compare the Price/Earnings ratio to 27.24, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 29.44 indicates a quite expensive valuation of MEDP.
Compared to the rest of the industry, the Price/Forward Earnings ratio of MEDP indicates a somewhat cheap valuation: MEDP is cheaper than 62.96% of the companies listed in the same industry.
MEDP's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 22.81.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 34.47 | ||
| Fwd PE | 29.44 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MEDP indicates a somewhat cheap valuation: MEDP is cheaper than 64.81% of the companies listed in the same industry.
MEDP's Price/Free Cash Flow ratio is rather cheap when compared to the industry. MEDP is cheaper than 81.48% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 22.46 | ||
| EV/EBITDA | 25.62 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
MEDP has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)2.56
PEG (5Y)1.04
EPS Next 2Y11.66%
EPS Next 3Y11.54%
5. Dividend
5.1 Amount
No dividends for MEDP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
463.64
+10.3 (+2.27%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners91.22%
Inst Owner Change4.05%
Ins Owners0.55%
Ins Owner Change5.09%
Market Cap13.02B
Analysts54.12
Price Target415.99 (-10.28%)
Short Float %11.24%
Short Ratio4.62
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.2%
Min EPS beat(2)2.57%
Max EPS beat(2)17.84%
EPS beat(4)4
Avg EPS beat(4)12.05%
Min EPS beat(4)2.57%
Max EPS beat(4)21.62%
EPS beat(8)8
Avg EPS beat(8)12.09%
EPS beat(12)11
Avg EPS beat(12)14.32%
EPS beat(16)15
Avg EPS beat(16)14.6%
Revenue beat(2)2
Avg Revenue beat(2)6.91%
Min Revenue beat(2)4.04%
Max Revenue beat(2)9.78%
Revenue beat(4)2
Avg Revenue beat(4)2.21%
Min Revenue beat(4)-3.35%
Max Revenue beat(4)9.78%
Revenue beat(8)3
Avg Revenue beat(8)0.5%
Revenue beat(12)7
Avg Revenue beat(12)1.63%
Revenue beat(16)8
Avg Revenue beat(16)1%
PT rev (1m)34.99%
PT rev (3m)35.62%
EPS NQ rev (1m)4.1%
EPS NQ rev (3m)15.16%
EPS NY rev (1m)10.25%
EPS NY rev (3m)10.71%
Revenue NQ rev (1m)5.14%
Revenue NQ rev (3m)17.4%
Revenue NY rev (1m)12.61%
Revenue NY rev (3m)12.71%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 34.47 | ||
| Fwd PE | 29.44 | ||
| P/S | 5.84 | ||
| P/FCF | 22.46 | ||
| P/OCF | 21.21 | ||
| P/B | 75.56 | ||
| P/tB | N/A | ||
| EV/EBITDA | 25.62 |
EPS(TTM)13.45
EY2.9%
EPS(NY)15.75
Fwd EY3.4%
FCF(TTM)20.64
FCFY4.45%
OCF(TTM)21.86
OCFY4.72%
SpS79.45
BVpS6.14
TBVpS-18.65
PEG (NY)2.56
PEG (5Y)1.04
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 26.61% | ||
| ROE | 242.7% | ||
| ROCE | 135.95% | ||
| ROIC | 115.03% | ||
| ROICexc | 132.51% | ||
| ROICexgc | N/A | ||
| OM | 21.4% | ||
| PM (TTM) | 18.74% | ||
| GM | 31.62% | ||
| FCFM | 25.98% |
ROA(3y)18.14%
ROA(5y)15.16%
ROE(3y)54.33%
ROE(5y)40%
ROIC(3y)38.75%
ROIC(5y)29.27%
ROICexc(3y)71.87%
ROICexc(5y)52.56%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)47.22%
ROCE(5y)35.45%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3Y64.05%
ROICexc growth 5Y48.31%
OM growth 3Y6.82%
OM growth 5Y7.46%
PM growth 3Y6.48%
PM growth 5Y10.5%
GM growth 3Y2.7%
GM growth 5Y1.75%
F-Score8
Asset Turnover1.42
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 118.36% | ||
| Cap/Sales | 1.54% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 121.25% | ||
| Profit Quality | 138.61% | ||
| Current Ratio | 0.43 | ||
| Quick Ratio | 0.43 | ||
| Altman-Z | 6.85 |
F-Score8
WACC10.57%
ROIC/WACC10.88
Cap/Depr(3y)142.96%
Cap/Depr(5y)144.54%
Cap/Sales(3y)2.07%
Cap/Sales(5y)2.41%
Profit Quality(3y)141.71%
Profit Quality(5y)142.32%
High Growth Momentum
Growth
EPS 1Y (TTM)26.53%
EPS 3Y37.96%
EPS 5Y33.22%
EPS Q2Q%12.73%
EPS Next Y13.45%
EPS Next 2Y11.66%
EPS Next 3Y11.54%
EPS Next 5Y10.11%
Revenue 1Y (TTM)9.94%
Revenue growth 3Y22.68%
Revenue growth 5Y19.62%
Sales Q2Q%14.24%
Revenue Next Year16.8%
Revenue Next 2Y12.77%
Revenue Next 3Y11.6%
Revenue Next 5Y11.19%
EBIT growth 1Y25.19%
EBIT growth 3Y31.04%
EBIT growth 5Y28.55%
EBIT Next Year22.19%
EBIT Next 3Y13.33%
EBIT Next 5Y12.64%
FCF growth 1Y55.28%
FCF growth 3Y34.54%
FCF growth 5Y25.47%
OCF growth 1Y50.59%
OCF growth 3Y32.23%
OCF growth 5Y24.7%